成人Ph染色体阴性急性淋巴细胞白血病的治疗进展

Advances on the treatment of adult Ph chromosome-negative acute lymphoblastic leukemia

虽然成人Ph染色体阴性的急性淋巴细胞(Ph-ALL)的治疗效果落后于儿童急性淋巴细胞白血病,但是随着对ALL生物学特点认识的进展治疗效果也取得进展,与儿童ALL疗效差距正在逐渐缩小。在青少年和年轻成人急性淋巴细胞白血病患者中采用儿童化疗方案、根据患者的遗传学特点和微小残留病变进行危险性分层并调整缓解后治疗进一步提高了患者的治疗效果。近年来,以单克隆抗体为基础的免疫治疗在成人Ph-ALL的治疗中取得初步成功。现将近年来Ph-ALL的治疗进展做一简要总结。

Although the therapeutic effect of adult Ph chromosome negative acute lymphocyte (Ph-ALL) is lagging behind that of childhood acute lymphoblastic leukemia, the gap is gradually narrowing with the progress of understanding the biological characteristics of ALL, which is transforming the progress of therapeutic effect. In adolescents and young adults with acute lymphoblastic leukemia adapted from pediatric protocols,risk stratification based on genetic characteristics and minimal residual disease, and adjustment of post-remission treatment further improve the therapeutic effect of patients. In recent years, immunotherapy based on monoclonal antibodies has achieved initial success in the treatment of adult Ph-ALL. In this paper, the recent developments on the treatment of Ph-ALL is briefly summarized.